Comparative Pharmacology
Head-to-head clinical analysis: CEFEPIME IN PLASTIC CONTAINER versus VELOSEF 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFEPIME IN PLASTIC CONTAINER versus VELOSEF 500.
CEFEPIME IN PLASTIC CONTAINER vs VELOSEF '500'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3. It demonstrates broad-spectrum activity against gram-positive and gram-negative bacteria, including Pseudomonas aeruginosa.
Cephradine inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis, leading to cell lysis and death. It is a first-generation cephalosporin with bactericidal activity.
1-2 g intravenously every 8-12 hours for moderate to severe infections; up to 2 g every 8 hours for severe infections or febrile neutropenia.
500 mg orally every 6 hours for 10 days.
None Documented
None Documented
2.0–2.3 hours in adults with normal renal function; prolonged to 13–26 hours in end-stage renal disease.
Terminal elimination half-life: 1.2 hours in adults with normal renal function; prolonged to 8-15 hours in severe renal impairment (CrCl <10 mL/min); clinical context: dosing interval adjustment required for renal impairment
Renal: approximately 85% of the dose excreted unchanged in urine; biliary/fecal: less than 1%.
Renal excretion of unchanged drug: >90% (glomerular filtration and tubular secretion); biliary/fecal: <1%
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic